BridgeBio Pharma Inc vs Stanley Black & Decker, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Stanley Black & Decker, Inc. trades at $104 (market cap $15.50B). The key difference: BridgeBio Pharma Inc and Stanley Black & Decker, Inc. are close in size by market cap, and Stanley Black & Decker, Inc. pays a 3.27% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SWK | |
|---|---|---|
Market Cap | $16.61B | $15.50B |
Sector | Health | — |
52-Week High | $90.17 | $104.00 |
52-Week Low | $47.29 | $62.12 |
Enterprise Value | $18.16B | $19.67B |
Dividend Yield | — | 3.27% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →